A selective monoamine oxidase (MAO) b inhibitor (also known as l-deprenyl) used as an adjuvant treatment in the management of parkinson\u2019s disease and, at higher doses (at which it is no longer selective), sometimes used to treat depression refractory to more standard pharmacotherapies. Marketed under the brand name eldepryl.<\/p>\n
A drug used in conjunction with levodopa to treat severe parkinsonism. Early treatment with selegiline may delay the need to give the patient levodopa, but at present there is no firm evidence that it slows down the progression of the disease.<\/p>\n
Selegiline is a medication employed for managing Parkinson’s disease. It can be administered either on its own during the initial phases of the disease or in conjunction with levodopa. Additionally, selegiline is utilized to address parkinsonism symptoms stemming from causes like repeated head injuries; it isn’t employed when the symptoms are drug-related. Potential side effects encompass nausea, vomiting, diarrhea or constipation, dry mouth, and sore throat.<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
A selective monoamine oxidase (MAO) b inhibitor (also known as l-deprenyl) used as an adjuvant treatment in the management of parkinson\u2019s disease and, at higher doses (at which it is no longer selective), sometimes used to treat depression refractory to more standard pharmacotherapies. Marketed under the brand name eldepryl. A drug used in conjunction with […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"class_list":["post-29313","post","type-post","status-publish","format-standard","hentry","category-s"],"yoast_head":"\n